DOXYMED Trademark

Trademark Overview

On Friday, March 18, 2022, a trademark application was filed for DOXYMED with the United States Patent and Trademark Office. The USPTO has given the DOXYMED trademark a serial number of 97319456. The federal status of this trademark filing is REGISTERED as of Tuesday, November 26, 2024. This trademark is owned by Right2Try Inc.. The DOXYMED trademark is filed in the Chemical Products category with the following description:

Pharmaceutical compositions and medicaments for use in the treatment of cancer; Pharmaceutical compositions and medicaments for use in treatment of a disease or condition in a subject, namely, reducing cancer stem cells, reducing tumor initiation, reducing metastatic spread; Pharmaceutical compositions and medicaments for use in treatment of a disease or condition in a subject, namely, increasing cytostatic and cyclotoxic activity of tumor cell lines; Pharmaceutical compositions and medicaments for use in treatment of a disease or condition in a subject, namely, inhibiting the activity of one or more matrix metalloproteinases; compositions and medicaments for use in the treatment of cancer
doxymed

General Information

Serial Number97319456
Word MarkDOXYMED
Filing DateFriday, March 18, 2022
Status700 - REGISTERED
Status DateTuesday, November 26, 2024
Registration Number7580578
Registration DateTuesday, November 26, 2024
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 19, 2023

Trademark Statements

Goods and ServicesPharmaceutical compositions and medicaments for use in the treatment of cancer; Pharmaceutical compositions and medicaments for use in treatment of a disease or condition in a subject, namely, reducing cancer stem cells, reducing tumor initiation, reducing metastatic spread; Pharmaceutical compositions and medicaments for use in treatment of a disease or condition in a subject, namely, increasing cytostatic and cyclotoxic activity of tumor cell lines; Pharmaceutical compositions and medicaments for use in treatment of a disease or condition in a subject, namely, inhibiting the activity of one or more matrix metalloproteinases; compositions and medicaments for use in the treatment of cancer

Classification Information

International Class001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins; unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry.
US Class Codes001, 005, 006, 010, 026, 046
Class Status Code6 - Active
Class Status DateWednesday, March 23, 2022
Primary Code001
First Use Anywhere DateFriday, March 18, 2022
First Use In Commerce DateMonday, July 1, 2024

Trademark Owner History

Party NameRight2Try Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressLewes, DE 19958
Party NameRight2Try Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressLewes, DE 19958
Party NameRight2Try Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressLewes, DE 19958

Trademark Events

Event DateEvent Description
Wednesday, February 15, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, March 23, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, December 29, 2022ASSIGNED TO EXAMINER
Friday, December 30, 2022NON-FINAL ACTION WRITTEN
Friday, December 30, 2022NON-FINAL ACTION E-MAILED
Friday, December 30, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, February 15, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, February 16, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, April 14, 2023NON-FINAL ACTION WRITTEN
Friday, April 14, 2023NON-FINAL ACTION E-MAILED
Friday, April 14, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, June 8, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, June 8, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, June 8, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Saturday, June 17, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, July 4, 2023WITHDRAWN FROM PUB - OG REVIEW QUERY
Monday, July 17, 2023PREVIOUS ALLOWANCE COUNT WITHDRAWN
Thursday, August 10, 2023NON-FINAL ACTION WRITTEN
Thursday, August 10, 2023NON-FINAL ACTION E-MAILED
Thursday, August 10, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, November 6, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, November 6, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, November 7, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, November 9, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, November 29, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, December 19, 2023PUBLISHED FOR OPPOSITION
Tuesday, December 19, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, February 13, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, July 29, 2024USE AMENDMENT FILED
Monday, July 29, 2024TEAS STATEMENT OF USE RECEIVED
Sunday, September 29, 2024STATEMENT OF USE PROCESSING COMPLETE
Sunday, September 29, 2024CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, October 21, 2024NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Tuesday, November 26, 2024REGISTERED-PRINCIPAL REGISTER
Tuesday, November 26, 2024NOTICE OF REGISTRATION CONFIRMATION EMAILED
Monday, October 21, 2024ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED

Related Keywords

doxymed medicaments treatment compositions pharmaceutical namely reducing subject disease condition cancer